American journal of ophthalmology
-
Randomized Controlled Trial
Surveillance of the eye and vision in clinical trials of CP-675,206 for metastatic melanoma.
To determine the ocular safety of CP-675,206 (Pfizer, New York, New York, USA), a fully human anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody in clinical trials of immunotherapy of metastatic melanoma. ⋯ In this study, CP-675,206 immunotherapy for metastatic melanoma did not adversely affect the eye or vision.